about
Placebo, nocebo, and neuropathic painCatechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responsesUnderstanding placebo and nocebo responses for pain management.Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measuresMolecular mechanisms of placebo responses in humans.Placebo analgesia: understanding the mechanisms.Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response.Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized TrialAssociation Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.Nonpharmacological Interventions in Targeting Pain-Related Brain PlasticityThe placebo effect: From concepts to genes.Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.Nocebo vs. placebo: the challenges of trial design in analgesia research.Genetics and the placebo effect: the placebome.Role of placebo effects in pain and neuropsychiatric disorders.Mechanisms of the placebo effect in pain and psychiatric disorders.Transmission pathways and mediators as the basis for clinical pharmacology of pain.Placebo-related effects: a meta-narrative review of conceptualization, mechanisms and their relevance in rheumatology.Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders.Interactions between dietary oil treatments and genetic variants modulate fatty acid ethanolamides in plasma and body weight composition.Mechanisms of placebo analgesia: A dual-process model informed by insights from cross-species comparisons.Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant.Genome-wide association studies of placebo and duloxetine response in major depressive disorder.Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.Creating placebo responders and nonresponders in the laboratory: boons and banes.
P2860
Q28072351-144AEF01-922E-4930-B019-6918B06CD425Q28542991-AEFD1306-F0F7-4627-9280-AA470D3FF382Q34081833-D305260F-4D53-47E1-9BFB-3D7A12DEFA04Q35089406-8D08B783-5A8B-44EC-A07E-2BFA2918027BQ35214124-554338E2-0436-47BA-B8E2-5D3340498108Q35297961-1A1DCFE0-E069-462E-AABD-777E5BA93D8FQ36382450-E2B44C58-25D9-42F7-8D95-EC5B3A50DE5FQ36540812-7260F5DE-3E26-4B73-ABEE-9BCD63B61648Q36593892-A96F46AB-64A2-412A-87FE-FD1969D30C56Q37680974-1F99CB08-A23F-4C2D-9654-BFE763D946F8Q37723087-E3EE4333-5572-4AA9-A3D5-9C66E930FE9AQ38283173-021A1B85-69A2-4523-AC06-974E250183ACQ38351533-A32025DB-A526-4754-BC60-A724023644AEQ38425277-4911AD26-4EBA-4936-A5B1-1DE0B5E4A0D0Q38673105-A3E10892-997B-47B5-91DF-22EFC5B861EDQ38784077-74E66349-9EBB-4A6F-A360-4A2EAB839506Q38870522-4B218E0A-5D89-4654-A12B-CC881F1B9679Q38914498-807915A6-58DE-4C1C-81BC-5E9418BD1506Q38935410-8B5C382F-1ABD-497B-A466-CBC3AC9883DBQ40066269-0110DB9F-B292-4A43-B2F7-345F8B1F03F1Q43075563-6FFC2206-9CEA-4DB2-8B71-51F3163F069AQ46413281-930E7E93-2327-48D4-B21C-CBE22DD77EC5Q47671240-8F23165A-4104-4B3C-A422-E044DF6DC3FFQ47958585-0BFF6742-D321-47BB-B706-AB0A5634FF3BQ50653849-2249D90D-C1DE-4B75-8A8C-12D6331AB883
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
FAAH selectively influences placebo effects.
@ast
FAAH selectively influences placebo effects.
@en
FAAH selectively influences placebo effects.
@nl
type
label
FAAH selectively influences placebo effects.
@ast
FAAH selectively influences placebo effects.
@en
FAAH selectively influences placebo effects.
@nl
prefLabel
FAAH selectively influences placebo effects.
@ast
FAAH selectively influences placebo effects.
@en
FAAH selectively influences placebo effects.
@nl
P2093
P2860
P356
P1433
P1476
FAAH selectively influences placebo effects.
@en
P2093
C Hodgkinson
C S Stohler
J K Zubieta
M Martínez-Jauand
P2860
P2888
P304
P356
10.1038/MP.2013.124
P407
P577
2013-09-17T00:00:00Z